Retatrutide (LY3437943) is a groundbreaking, single-peptide triple agonist targeting three critical metabolic pathways: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. Synthetically engineered for structural stability and enhanced potency, this first-in-class multi-incretin mimetic is at the forefront of contemporary obesity and metabolic disease research.
Verified by mass spectrometry at 4,731.3 Da with ≥99% purity, our Retatrutide is formulated to deliver exceptional consistency and stability for advanced laboratory applications.
Key Research Areas:
• Triple Receptor Agonism: Simultaneously engages the GIP, GLP-1, and glucagon receptors, providing a synergistic approach to metabolic regulation that surpasses traditional mono- or dual-agonist profiles.
• Adipose & Weight Modulation: Heavily investigated for its robust impact on lipolysis and visceral fat reduction, driven by combined appetite suppression and glucagon-mediated energy expenditure.
• Glycemic Control Optimization: Promotes glucose-dependent insulin secretion and stabilizes glucose homeostasis, making it a primary subject in type 2 diabetes and insulin sensitivity research.
• Hepatic & Metabolic Health: Studied for its potential to influence lipid profiles, reduce liver steatosis (fat accumulation), and support systemic metabolic tissue remodeling.
For research purposes only.
Wesley G –
Reta is honest to god a miracle drug. Not only have I dropped 30 lbs of stubborn belly fat I feel better than I have in my entire life. And at this price point you can’t beat it!